SCIENTIFIC HUB

Araştırmanın izini sürün.

SCIENTIFIC LITERATURE · MED

Modulators selectively reshape α-synuclein phase transitions.

J Chem Phys · 2026-10-01

DOI: 10.1063/5.0354094PMID: 42867852

Erişim kaynaktan kontrol edilmeliJournal ArticleKaynağa git ↗

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Protein phase transitions govern numerous diseases, including neurodegenerative disorders. In Parkinson's disease, distinct species of the protein α-synuclein undergo phase transitions from disordered to ordered β-rich states. The emerging species and transitions between them can be reshaped by modulators, e.g., small molecules, peptides or antibodies. Here, we use coarse-grained simulations to understand the effect of modulators on the thermodynamics and kinetics of α-synuclein phase transitions. Each protein is represented as a morphing particle that transforms from a soft sphere (disordered) to a hard spherocylinder (β-rich). Modulators are modeled as soft isotropic particles mimicking peptides. Purely repulsive modulators do not alter the final outcome; that is, fibrils form following the same mechanisms independently of the modulator concentration. Attractive interactions toward the disordered protein dose-dependently slow down fibrillization by stabilizing intermediate species, including persistent disordered heteroclusters. Specific attraction to the β-rich state shortens fibrils through direct modulator surface "capping" that introduces kinetic barriers to monomer templating at the fibril ends and inhibits fibril elongation. Overall, these results link modulator properties and environmental conditions to nucleation, fibril elongation, and off-pathway trapping, providing a quantitative roadmap for designing interventions that redirect phase transitions toward desirable endpoints.

Bilimsel değerlendirme

01

Araştırma sorusu

Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.

02

Yöntem ve örneklem

Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.

03

Temel bulgular

Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.

04

Sınırlılıklar

Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.

Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.